Clinical Trial Update: Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo. [Phase 1]

View source ↗

Summary

Phase 1 scintigraphy study to assess gastric emptying in healthy subjects given GSK716155 or placebo; the trial completed and was sponsored by GlaxoSmithKline.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• GSK716155

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED